UiPath Raises $568 Million Series D Funding Round
The leading robotic process automation (RPA) software company, UiPath, is blazing a path to an “automation first” era, closing its Series D investment round raising $568 million at a post-money valuation of $7 billion, led by Coatue and joined by Dragoneer, Wellington, Sands Capital, and funds and accounts advised by T. Rowe Price Associates, Inc. Accel, who led the Series A and B rounds, and CapitalG and Sequoia who led the Series C round, all participated in this round, as did other existing investors, including IVP and Madrona Venture Group. At the $7 billion valuation, UiPath is one of the fastest growing and highest-valued AI enterprise software companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190430005133/en/
UiPath Growth Over 24 Months (Graphic: Business Wire)
UiPath closed its Series A funding in April 2017, and since then has expanded on its most important milestones:
- Cultivated the world’s largest community in RPA, now exceeding 400,000 users worldwide across 200 countries;
- Expanded its worldwide customer base to eight of the top 10 Fortune Global 500, and over 50 percent of the top 50 Fortune Global 500;
- Delivered six releases of the UiPath Enterprise RPA platform with defense-grade security, launched UiPath Go!, integrated AI by adding new capabilities like AI Computer Vision, and created an open and extensible architecture that has made UiPath the platform of choice for third-party RPA and AI development;
- Increased annual recurring revenue (ARR) from $8 million to over $200 million; and
- Grew its employee base to over 2,500, a 16x increase during the period.
“We are at the tipping point. Business leaders everywhere are augmenting their workforces with software robots, rapidly accelerating the digital transformation of their entire business and freeing employees to spend time on more impactful work,” said Daniel Dines, UiPath co-founder and CEO. “UiPath is leading this workforce revolution, driven by our core determination to democratize RPA and deliver on our vision of a robot helping every person. I am humbled by the amazing support our customers, partners and investors give us every day, inspiring us to work harder to evolve RPA as the platform that not only unlocks the true potential of AI, but also other emerging technologies. We are just getting started.”
Recent customer additions include American Fidelity, BankUnited, CWT (formerly known as Carlson Wagonlit Travel), Duracell, Google, Japan Exchange Group (JPX), LogMeIn, McDonalds, NHS Shared Business Services, Nippon Life Insurance Company, NTT Communications Corporation, Orange™, Ricoh Company, Ltd., Rogers Communications, Shinsei Bank, Quest Diagnostics, Uber, US Navy, Voya Financial, Virgin Media, and World Fuel Services.
UiPath’s commitment to delivering the best RPA solution and creating a powerful, open, and transparent team has garnered significant recognition:
- Listed to CB Insights’ AI 100, a list showcasing the 100 most promising private AI companies in the world;
- Named to the Forbes 2018 Cloud 100, snagging the 14th spot on the list;
- Ranked the 26th fastest growing company in North America on the 2018 Deloitte Fast 500;
- Named a leader in The Forrester Wave™: Robotic Process Automation, Q2 2018; and
- Given more than 10 Comparably Awards in categories including: Best Place to Work, Best Places to Work in New York region, Best Outlook (large companies), Happiest Employees, Best Engineering Teams 2019, Best Product Teams 2019, Best Company for Women, Diversity, Perks & Benefits, and Compensation.
“UiPath is improving business performance, efficiency and operation in a way we’ve never seen before,” said Philippe Laffont, founder of Coatue Management. “The Company’s rapid growth over the last two years is a testament to the fact that UiPath is transforming how companies manage their resources. RPA presents an enormous opportunity for companies around the world who are embracing artificial intelligence, driving a new era of productivity, efficiency and workplace satisfaction.”
“UiPath is enabling the critical capabilities necessary to advance how companies perform and how employees better spend their time,” said Greg Dunham, vice president at T. Rowe Price Associates, Inc. “The industry has achieved rapid growth in such a short time, with UiPath at the head of it, largely due to the fact that RPA is becoming recognized as the paradigm shift needed to drive digital transformation through virtually every single industry in the world.”
UiPath is leading the “automation first” era – championing one robot for every person, delivering free and open training and collaboration and enabling robots to learn new skills through AI and machine learning. Led by a commitment to bring digital era skills to more than a million people, the company’s enterprise Robotic Process Automation (RPA) platform has already automated millions of repetitive, mind-numbing tasks for business and government organizations all over the world, improving productivity, customer experience and employee job satisfaction.
Recently named by Comparably as the 6th happiest place to work and the 11th best company culture among large businesses, UiPath is one of the fastest growing and highest-valued AI enterprise software companies worldwide.
All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of these names, trademarks and brands does not imply endorsement.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Assimoco Group Selects Moody’s Analytics SolvencyWatch ™ Solution29.5.2020 11:00:00 CEST | Press release
Moody’s Analytics, a global provider of financial intelligence, today announced that its software has been selected by Assimoco Group, an Italian insurance group and the insurance provider for the Italian Cooperative Movement since 1978. Assimoco Group will use the Moody’s Analytics SolvencyWatch solution to monitor key solvency metrics. Powered by Moody’s Analytics award-winning modeling capabilities, the SolvencyWatch solution quickly calculates an insurer’s assets and liabilities to reflect the latest market conditions, enabling chief risk officers (CROs) to monitor their solvency position in real time. The tool’s intuitive dashboard allows CROs and risk teams to visualize the impact on crucial solvency metrics under changes to market and non-market risks, and communicate to stakeholders what is driving changes in those metrics. “The Moody’s Analytics SolvencyWatch solution will allow us to monitor our solvency position frequently, accurately, and cost effectively,” said Ruggero Fre
Wipro Appoints Thierry Delaporte as CEO & Managing Director29.5.2020 07:21:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the appointment of Thierry Delaporte as the Chief Executive Officer and Managing Director of the company, effective July 6, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005916/en/ Thierry Delaporte (Photo: Business Wire) Until recently, Thierry Delaporte was the Chief Operating Officer of Capgemini Group and a member of its Group Executive Board. During his twenty-five year career with Capgemini, he held several leadership roles including that of Chief Executive Officer of the Global Financial Services Strategic Business Unit, and head of all global service lines. He also oversaw Capgemini’s India operations, and led the group’s transformation agenda, conceptualizing and driving several strategic programs across various business units. “I am delighted to
Ipsen Appoints David Loew as Chief Executive Officer29.5.2020 07:05:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005876/en/ David Loew, CEO at Ipsen as of July 1st 2020 (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Board of Directors has appointed David Loew as its new Chief Executive Officer (CEO) and as Board member. The CEO appointment will take effect on July 1st, 2020. The Board of Directors expresses its gratitude to Aymeric Le Chatelier, who steered the group very well in an exceptionally challenging environment and who will remain in the role of acting CEO until July 1st, 2020 and will continue in his role of Chief Financial Officer. David Loew will be based at Ipsen’s headquarters in Boulogne-Billancourt, France. His mission will be to ensure Ipsen’s continued growth and to advance its pipeline via a long-term value-adding external innovation strategy, while fostering a culture of entrepreneurship, agility and patient-cent
New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CEST | Press release
Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a
European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr
Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CEST | Press release
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit